Table 1.
Baseline characteristics of studies.
| Source | Study | Phase | Treatment | Participants No. | ORR, No./total No. (%) | PFS, median, m | HR (95% CI) | p-value | OS, median, months | HR (95% CI) | p-value | Grade ≥ 3 AEs No./total No. (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reck 2013 |
CA184-041 | III | Concurrent-Ipilimumab plus paclitaxel/carboplatin | 43 | 21/43 (48.83) | 5.7 (5.2–6.9) | 0.75 (0.48–1.19) | 0.11 | 9.1 (6.7–12.9) | 0.95 (0.59–1.54) | 0.41 | 18/42 (43) |
| 14/43 (32.56) | 3.9 (2.9–5.9) | 0.93 (0.59–1.45) | 0.37 | |||||||||
| Phased-Ipilimumab plus paclitaxel/carboplatin | 42 | 30/42 (71.43) | 6.4 (5.3–7.6) | 0.64 (0.40–1.02) | 0.03 | 12.9 (7.9–16.5) | 0.75 (0.46–1.23) | 0.13 | 21/42 (50) | |||
| 24/42 (57.14) | 5.2 (4.14–6.57) | 0.93 (0.59–1.48) | 0.38 | |||||||||
| Placebo plus paclitaxel/carboplatin | 45 | 24/45 (53.33) | 5.3 (4.7–5.7) | 9.9 (8.6–11.7) | 13/44 (30) | |||||||
| Reck 2016 |
CA184-156 | III | Ipilimumab plus etoposide and platinum | 478 | 297/478 (62.1) | 4.6 (4.5–5.0) | 0.85(0.75–0.97) | 0.02 | 11 (10.5–11.3) | 0.94 (0.81–1.09) | 0.377 | 231/478 (48.3) |
| Placebo plus etoposide and platinum | 476 | 196/476 (41.2) | 4.4 (4.4–4.6) | 10.9 (10–11.5) | 214/476 (45.0) | |||||||
| Horn 2018 |
IMpower133 | III | Atezolizumab plus carboplatin and etoposide | 201 | 121/201 (60.2) | 5.2 (4.4–5.6) | 0.77(0.62–0.96) | 0.02 | 12.3 (10.8–15.9) | 0.70 (0.54–0.91) | 0.007 | 115/198 (58.1) |
| placebo plus carboplatin and etoposide | 202 | 130/202 (64.4) | 4.3 (4.2–4.5) | 10.3 (9.3–11.3) | 113/196 (57.7) | |||||||
| Ticiana 2020 |
EA5161 | II | Nivolumab plus cisplatin/carboplatin and etoposide | 80 | 42/80 (52.29) | 5.5 | 0.68 (0.48–1.00) | 0.047 | 11.3 | 0.73 (0.49–1.1) | 0.14 | 67/75 (89.33) |
| cisplatin/carboplatin and etoposide | 80 | 38/80 (47.71) | 4.7 | 9.3 | 50/70 (71.43) | |||||||
| Paz-Ares 2019-2022 |
CASPIAN | III | Durvalumab plus tremelimumab plus platinum-etoposide | 268 | 156/267 (58.4) | 4.9 (4.7–5.9) | 0·84 (0.7–1.01) | NR | 10.4 (9.5–12) | 0·81 (0·67–0.97) | 0·045 | 196/266 (73.68) |
| Durvalumab plus platinum-etoposide | 268 | 182/268 (67.9) | 5.1 (4.7–6.2) | 0·80(0·66–0.96) | NR | 12.9 (11.3–14.7) | 0.71 (0.60–0.86) | 0.003 | 171/265 (64.53) | |||
| Platinum-etoposide alone | 269 | 156/269 (58.0) | 5.4 (4.8–6.2) | 10.5 (9.3–11.2) | 173/266 (65.04) | |||||||
| Rudin 2022 |
KEYNOTE-604 | III | Pembrolizumab Plus Etoposide and Platinum | 228 | 161/228 (70.6) | 4.5 (4.3–5.4) | 0.75 (0.61– 0.91) | 0.0023 | 10.8 (9.2–12.9) | 0.80 (0.64–0.98) | 0.016 | 97/223 (43.5) |
| Placebo Plus Etoposide and Platinum | 225 | 139/225 (61.8) | 4.3 (4.2–4.4) | 9.7 (8.6–10.7) | 91/223 (40.8) | |||||||
| Wang 2022 |
CAPSTONE-1 | III | Adebrelimab plus carboplatin and etoposide | 230 | 162/230 (70.4) | 5.8 (5.6–6.9) | 0.67(0.54–0.83) | <0.0001 | 15.3 (13.2–17.5) | 0.72 (0.58–0.90) | 0.0017 | 197/230 (85.65) |
| placebo plus carboplatin and etoposide | 232 | 153/232 (65.9) | 5.6 (5.5–5.7) | 12.8 (11.3–13.7) | 197/232 (84.91) | |||||||
| Cheng 2022 |
ASTRUM-005 | III | Serplulimab plus carboplatin and etoposide | 389 | 312/389 (80.2) | 5.8 (5.5–6.9) | 0.47(0.38–0.59) | <0.001 | 15.4 (13.3–NE) | 0.63 (0.49–0.82) | <0.01 | 129/389 (33.2) |
| placebo plus carboplatin and etoposide | 196 | 138/196 (70.4) | 4.3 (4.2–4.5) | 10.9 (10–14.3) | 54/196 (27.6) | |||||||
| Rudin 2022 |
SKYSCRAPER-02 | III | Tiragolumab plus atezolizumab + carboplatin + etoposide | 243 | 172/243 (70.8) | 5.1 (4.4–5.4) | 1.08(0.89, 1.31) | NR | 13.1 (10.9–14.4) | 1.02 (0.80, 1.30) | NR | 166/239 (69.4) |
| atezolizumab + carboplatin + etoposide | 247 | 162/247 (65.6) | 5.4 (4.5–5.7) | 12.9 (12.1–14.5) | 173/246 (70.3) |
ES-SCLC, extensive-stage small cell lung cancer; HR, hazard ratio; NR, not reported; OS, overall survival; PFS, progression-free survival; ORR, objective response rate; Grade ≥ 3 AEs, adverse events of grade 3 or higher.